The Herpetic Keratitis drugs in development market research report provides comprehensive information on the therapeutics under development for Herpetic Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Herpetic Keratitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Herpetic Keratitis and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Herpetic Keratitis by nine companies/universities/institutes. The top development phase for Herpetic Keratitis is preclinical with six drugs in that stage. The Herpetic Keratitis pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Herpetic Keratitis pipeline products market are: Shulov Innovative Science, Fox Chase Chemical Diversity Center and Editas Medicine.
The key targets in the Herpetic Keratitis pipeline products market include Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35), Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1), and DNA.
The key mechanisms of action in the Herpetic Keratitis pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with one drug in Phase II. The Herpetic Keratitis pipeline products include five routes of administration with the top ROA being Ophthalmic and five key molecule types in the Herpetic Keratitis pipeline products market including Small Molecule, and Synthetic Peptide.
Herpetic Keratitis overview
Herpetic Keratitis is an inflammation or infection of cornea of the eye caused by HSV (herpes simplex virus). It is a viral infection and is classified as type-1 and type-2. Spread of HSV to the eyes causes herpetic keratitis. Presence of HSV infection and other triggering factors like exposure to direct sunlight, drug-induced, stress. Herpetic keratitis is further classified as epithelial keratitis, immune stromal keratitis, stromal necrotic, and endothelium. Conjunctivitis or red eyes is the common symptom that causes blurred vision, watery eyes, redness, sting, and irritation. Stopping the spread of infection is the preventive measure to be taken and topical anti-viral medications and steroids to treat pain and discomfort. Corneal transplant in complicated or severe cases is recommended.
For a complete picture of Herpetic Keratitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
